Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Learn how aging affects your hands and get expert tips to maintain hand health, manage age-related conditions, and prevent ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.

Eli Lilly’s experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase ...

In addition, the obesity drug also improved knee pain in participants, Eli Lilly noted. ・Seven additional Phase 3 trials for ...